Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 32Genitourinary 15Gastrointestinal 9Other hematologic neoplasm 6Lymphoid 6Plasma cell 4Sarcoma 3Breast 3NET 2Endocrine 2Tumor-Agnostic 1Thoracic 1Gynecologic 1CNS 1

Conditions

Peritoneal Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Introns × Gynecologic × Clear all
NCT02151448 2020-07-20

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

University of Pittsburgh

Phase 1/2 Completed
64 enrolled 18 charts
Gynecologic

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡